Live Breaking News & Updates on Peter Feinberg

Stay updated with breaking news from Peter feinberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Needham & Company LLC Reaffirms Buy Rating for Immuneering (NASDAQ:IMRX)

Needham & Company LLC Reaffirms Buy Rating for Immuneering (NASDAQ:IMRX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Peter Feinberg , Immuneering Corporation , Financial Services Group Inc , Td Asset Management Inc , Securities Exchange Commission , Corton Capital Inc , Needham Company , Get Free Report , Stock Down , Cormorant Asset Management , Exchange Commission , Director Peter Feinberg , Management Inc , Capital Partners , Services Group , Investigational New Drug , Immuneering Daily ,

Immuneering Co. (NASDAQ:IMRX) Director Purchases $63,750.00 in Stock

Immuneering Co. (NASDAQ:IMRX – Get Free Report) Director Peter Feinberg acquired 25,000 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were bought at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the acquisition, the director now directly owns 111,766 shares […] ....

Peter Feinberg , Immuneering Company Profile , Virtu Financial , Nuveen Asset Management , Immuneering Corporation , Vanguard Group Inc , Securities Exchange Commission , Jefferies Financial Group , Oracle Alpha Inc , Immuneering Co , Needham Company , Barclays Plc , Get Free Report , Director Peter Feinberg , Exchange Commission , Stock Down , Asset Management , Oracle Alpha , Financial Group , Chardan Capital , Investigational New Drug , Immuneering Daily , Nasdaq Imrx , Insider Trading , Nsider Trades ,

Insider Buying: Immuneering Co. (NASDAQ:IMRX) Director Acquires 25,000 Shares of Stock

Immuneering Co. (NASDAQ:IMRX – Get Free Report) Director Peter Feinberg bought 25,000 shares of the company’s stock in a transaction dated Friday, March 22nd. The stock was bought at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the acquisition, the director now owns 111,766 shares of the company’s stock, […] ....

Peter Feinberg , Needham Company , Pricet Rowe Associates Inc , Immuneering Co , Jefferies Financial Group , Vanguard Group Inc , Immuneering Corporation , Blackrock Inc , Citadel Advisors , Get Free Report , Director Peter Feinberg , Trading Down , Asset Management , Vanguard Group , Investigational New Drug , Immuneering Daily ,